Antibiotic resistance patterns of more than 120 000 clinical Escherichia coli isolates in Southeast Austria, 1998-2013

Clinical Microbiology and Infection

Volumn 21, Issue 6, 2015, Pages 569.e1-569.e7

  Badura, A ^a   Feierl, G ^a   Pregartner, G ^b   Krause, R ^c   Grisold, A J ^a  

^a Microbiology and Environmental Medicine   (Austria)

^b Institute for Medical Informatics   (Austria)

^c MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Antibiotic resistance; Austria; Epidemiology; ESBL; Escherichia coli

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; MEROPENEM; NITROFURANTOIN; PIPERACILLIN PLUS TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; AUSTRIA; BACTERIUM ISOLATION; CHILD; FEMALE; GENDER; HOSPITAL PATIENT; HOST PARASITE INTERACTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NONHUMAN; OUTPATIENT; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; ADOLESCENT; AGED; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG EFFECTS; ENZYMOLOGY; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD; SECRETION (PROCESS); SEX DIFFERENCE; VERY ELDERLY; YOUNG ADULT;

ESCHERICHIA COLI;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AUSTRIA; BETA-LACTAMASES; CHILD; CHILD, PRESCHOOL; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; SEX FACTORS; YOUNG ADULT;

EID: 84930788761     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1016/j.cmi.2015.02.012     Document Type: Article

References (26)

1. Kaper J.B., Nataro J.P., Mobley H.L.T. Pathogenic Escherichia coli. Nat Rev Microbiol 2004, 2:123-140.
2. European Centre for Disease Prevention and Control Antimicrobial resistance surveillance in Europe, 2012. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2013, European Centre for Disease Prevention and Control, Stockholm.
3. Livermore D.M. Current epidemiology and growing resistance of Gram-negative pathogens. Korean J Intern Med 2012, 27:128-142.
4. Pitout J.D.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
5. Nordmann P., Naas T., Poirel L. Global spread of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011, 7:1791-1798.
6. Bedenic B., Goic-Barisic I., Budimir A., Tonkic M., Mihajkevic L.J., Novak A., et al. Antimicrobial susceptibility and beta-lactamase production of selected Gram-negative bacilli from two Croatian hospitals: MYSTIC study results. JChemother 2010, 22:147-152.
7. Farrell D.J., Sader H., Putnam S.D., Jones R.N. Multicenter evaluation of tigecycline activity in Latin America: report from the SENTRY antimicrobial surveillance program (2009). Int J Infect Dis 2010, 14:E344-E345.
8. Hawser S.P., Bouchillon S.K., Lascols C., Hackel M., Hoban D.J., Badal R.E., et al. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum beta-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009). Clin Microbiol Infect 2012, 18:253-259.
9. Norskov-Lauritsen N., Marchandin H., Dowzicky M.J. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009, 34:121-130.
10. Bris C., Auger G., Kowalczyk F., Eveillard M., Joly-Guillou M.L., Kempf M. Invitro activity of tigecycline on 760 bacterial strains isolated in the hospital university of Angers-2006-2009 TEST study. Pathol Biol 2012, 60:336-339.
11. Kronenberg A., Hilty M., Endimiani A., Muehlemann K. Temporal trends of extended-spectrum cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae isolates in in- and outpatients in Switzerland, 2004 to 2011. Euro Surveill 2013, 18:24-33.
12. Clinical and Laboratory Standards Institute Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement 2011, CLSI document M100-S21, Clinical and Laboratory Standards Institute, Wayne, PA.
13. R Development Core Team R: a language and environment for statistical computing 2008, R Foundation for Statistical Computing, Vienna.
14. Bush K., Courvalin P., Dantas G., Davies J., Eisenstein B., Huovinen P., et al. Tackling antibiotic resistance. Nat Rev Microbiol 2011, 9:894-896.
15. Leverstein-van Hall M.A., Waar K., Muilwijk J. Stuart JC; ISIS-AR Study Group. Consequences of switching from a fixed 2:1 ratio of amoxicillin/clavulanate (CLSI) to a fixed concentration of clavulanate (EUCAST) for susceptibility testing of Escherichia coli. JAntimicrob Chemother 2013, 68:2636-2640.
16. Wolfensberger A., Sax H., Weber R., Zbinden R., Kuster S.P., Hombach M. Change of antibiotic susceptibility testing guidelines from CLSI to EUCAST: influence on cumulative hospital antibiograms. Plos One 2013, 8:e79130.
17. Canton R., Akova M., Carmeli Y., Giske C.G., Glupczynski Y., Gniadkowski M., et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012, 18:413-431.
18. Dimou V., Dhanji H., Pike R., Livermore D.M., Woodford N. Characterization of Enterobacteriaceae producing OXA-48-like carbapenemases in the UK. JAntimicrob Chemother 2012, 67:1660-1665.
19. Glupczynski Y., Huang T., Bouchahrouf W., de Castro R.R., Bauraing C., Gerard M., et al. Rapid emergence and spread of OXA-48-producing carbapenem-resistant Enterobacteriaceae isolates in Belgian hospitals. Int J Antimicrob Agents 2012, 39:168-172.
20. Nordmann P., Poirel L., Walsh T.R., Livermore D.M. The emerging NDM carbapenemases. Trends Microbiol 2011, 19:588-595.
21. da Costa P.M., Loureiro L., Matos A.J. Transfer of multidrug-resistant bacteria between intermingled ecological niches: the interface between humans, animals and the environment. Int J Environ Res Public Health 2013, 10:278-294.
22. Livermore D.M., Canton R., Gniadkowski M., Nordmann P., Rossolini G.M., Arlet G., et al. CTX-M: changing the face of ESBLs in Europe. JAntimicrob Chemother 2007, 59:165-174.
23. Miguel Sahuquillo-Arce J., Selva M., Perpinan H., Gobernado M., Armero C., Lopez-Quilez A., et al. Antimicrobial resistance in more than 100,000 Escherichia coli isolates according to culture site and patient age, gender, and location. Antimicrob Agents Chemother 2011, 55:1222-1228.
24. Bukh A.S., Schonheyder H.C., Emmersen J.M.G., Sogaard M., Bastholm S., Roslev P. Escherichia coli phylogenetic groups are associated with site of infection and level of antibiotic resistance in community-acquired bacteraemia: a 10 year population-based study in Denmark. JAntimicrob Chemother 2009, 64:163-168.
25. Quentin C., Arpin C., Dubois V., Andre C., Lagrange I., Fischer I., et al. Antibiotic resistance rates and phenotypes among isolates of Enterobacteriaceae in French extra-hospital practice. Eur J Clin Microbiol Infect Dis 2004, 23:185-193.
26. Livermore D.M., Nichols T., Lamagni T.L., Potz N., Reynolds R., Duckworth G. Ciprofloxacin-resistant Escherichia coli from bacteraemias in England; increasingly prevalent and mostly from men. JAntimicrob Chemother 2003, 52:1040-1042.